Boston

In the Lab By Elizabeth Cooney

‘A terrific choice’: George Church salutes fellow CRISPR pioneers’ historic Nobel win

Health By Eric Boodman

He’s a recruiter for a Covid-19 vaccine trial. Can he overcome communities’ distrust — and his own mother’s?

Biotech By Jonathan Saltzman — Boston Globe

Biotech looking to fight kidney disease launches with $51 million

Health Tech By Rebecca Robbins, Erin Brodwin, and Casey Ross

The health tech tracker for the fourth quarter: 14 pivotal industry events to watch

Health Tech By Larry Edelman — Boston Globe

Amwell rides IPO wave with expanded stock sale

Biotech By Andrew Joseph

Patent board delivers blow to University of California over its CRISPR invention claims

Biotech By Jonathan Saltzman — Boston Globe

Casma Therapeutics brings in another $50 million to target muscular dystrophy

Biotech By Jonathan Saltzman — Boston Globe

Korro Bio raises $90 million to fix mutations that cause diseases

Something Ventured By Kate Sheridan

Oncorus and three other startups got venture funding a year ago. Did it help them do what they said it would?

Health Tech By Andy Rosen — Boston Globe

Biofourmis raises $100 million for remote patient monitoring tools

Health By Elizabeth Cooney

Immigration status, housing, and food-service work explain Covid-19’s burden on Latinos

Biotech By Elizabeth Cooney

Foundation Medicine wins FDA approval for liquid biopsy able to detect mutations in multiple cancers 

In the Lab By Pratibha Gopalakrishna

Scientists create a synthetic lining for the intestine to make delivering drugs easier

Health Tech By Larry Edelman — Boston Globe

Telehealth company Amwell files to sell shares to public, Google

Health By Jonathan Saltzman — Boston Globe

Biogen conference likely led to 20,000 Covid-19 cases in Boston area, researchers say

Pharma By Adam Feuerstein

J&J to buy Momenta Pharma in a bid to bolster autoimmune disease pipeline

Health By Jonathan Saltzman — Boston Globe

‘We’re going to keep going’: A new clinical trial for ALS gives patients hope

Biotech By Kate Sheridan

4 questions for neurology startups as venture investors pour millions into the field

Biotech By Jonathan Saltzman — Boston Globe

Hospital president wrote opinion piece critical of drug pricing efforts, but didn’t disclose role on Moderna board

Biotech By Adam Feuerstein

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Biotech By Matthew Herper

Biogen strikes $1 billion deal with Denali to advance Parkinson’s drug based on approach that was nearly abandoned

Biotech By Jonathan Saltzman — Boston Globe

Prominent hospital president resigns from Moderna board after conflict of interest questions raised

Biotech By Damian Garde and Matthew Herper

Coles-led Cerevel Therapeutics to raise $445 million to develop brain drugs with fewer side effects

In the Lab By Elizabeth Cooney

A test you can breathe in: Scientists are developing synthetic biosensors to monitor lung disease

Biotech By Damian Garde

Ruling threatens to upend patents on Moderna’s Covid-19 vaccine